VectorBuilder Secures European Patent for MiniVec™ Plasmid System, Advancing Gene Therapy Manufacturing

VectorBuilder (搜索)搜索该词条, a global leader in gene delivery technologies and CDMO services, announced that its MiniVec™ (搜索)搜索该药品 plasmid system has been granted a European patent, marking a significant milestone for the company's proprietary plasmid DNA technology. The patent covers the underlying plasmid system design and associated production approaches, providing formal recognition of the technology's novelty and its applicability to modern genetic medicine development.

Revolutionary Design Eliminates Traditional Constraints

MiniVec™ (搜索)搜索该药品 was developed to address constraints that have historically limited plasmid safety, scalability, and regulatory acceptance. By minimizing bacterial-derived sequences on its plasmid backbone, the system eliminates the need for antibiotic selection and reliance on chemical additives for plasmid maintenance and fermentation.

"This patent reflects a fundamental shift in how plasmid systems can be designed for clinical use," said Dr. Bruce Lahn, Chief Scientist of VectorBuilder (搜索)搜索该词条. "Many of the challenges developers encounter later, whether in manufacturing, safety, or regulatory review, can be traced back to early design decisions. MiniVec™ (搜索)搜索该药品 was developed to remove these constraints at the source, improving how plasmids perform across the entire development pipeline."

Enhanced Manufacturing Efficiency

MiniVec™ (搜索)搜索该药品 is optimized to simplify plasmid production while improving output. Its miniaturized backbone supports antibiotic-free and additive-free production, reducing process complexity in GMP environments and showing consistent yield gains across vector types. The technology demonstrates particularly notable gains at manufacturing scale, directly lowering the cost of goods for GMP-grade plasmid production.

Superior Performance Across Therapeutic Applications

Compared to traditional plasmids, MiniVec™ (搜索)搜索该药品 achieved measurable performance improvements across multiple applications. The system demonstrated higher viral titers, higher CRISPR (搜索)搜索该靶点-mediated genome integration activity, consistent gains across transposon systems, and higher antibody titers in DNA vaccine models.

In cell therapy workflows, MiniVec™ (搜索)搜索该药品 showed significant improvement in T-cell electroporation efficiency compared to traditional plasmids, with direct implications for CAR-T (搜索)搜索该药品 manufacturing throughput and dose consistency. These improvements address critical bottlenecks in current cell therapy production processes.

Comprehensive Safety Profile

MiniVec™ (搜索)搜索该药品 has been systematically evaluated in vivo through acute and repeated-dose studies assessing hematological, biochemical, and organ-level parameters, with no adverse effects observed. This safety profile aligns with FDA and EMA expectations to remove antibiotic resistance genes and unnecessary genetic elements, supporting the development of clinically relevant plasmid systems.

Broad Applications and Future Prospects

The European patent milestone highlights MiniVec™ (搜索)搜索该药品's potential across multiple areas of genetic medicine, including cell and gene therapy, DNA vaccine development, and emerging in vivo therapeutic approaches. The technology's simplified and antibiotic-free design also provides advantages in fields such as food-alternative biotechnology, where regulatory requirements for genetic materials are particularly stringent.

Patent applications are expected to support ongoing considerations in other major markets, including the United States, Australia, Japan, Korea, and China. As demand for scalable, regulatory-ready plasmid systems grows, MiniVec™ (搜索)搜索该药品 is positioned to play an increasingly important role in supporting the next generation of genetic medicines and biologics.